Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Danielle Brazel, Shannon Zhang, Misako Nagasaka
Abstract
Abstract: Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1– 20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice. Keywords: tepotinib, capmatinib, mesenchymal-epithelial transition inhibitors, MET, RET, non-small cell lung cancer
Topics & Concepts
MedicineTolerabilityExonCancer researchLung cancerClinical trialReceptor tyrosine kinaseOncologyTyrosine-kinase inhibitorInternal medicineTyrosine kinaseClinical PracticeMutationBioinformaticsCancerGeneReceptorAdverse effectGeneticsFamily medicineBiologyLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCholangiocarcinoma and Gallbladder Cancer Studies